# Fuho Capital

> Fuho Capital is a VC fund in Haidian backing Health Care, Biotechnology and Medical. See 32 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Haidian, China
- Total investments: 32
- Last investment: Apr 2026
- Lead investor: 25%
- Last updated: Aug 2026
- Website: http://www.fuhocapital.com/

Fuho Capital is an equity investment fund management company.

## Round sizes

| Stage | Round size |
| --- | --- |
| Angel | $425k–$2.8M |
| Series A | $709k–$15M |
| Series B | $2.8M–$44M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 34% |
| Biotechnology | 10 | 31% |
| Medical | 8 | 25% |
| Pharmaceutical | 7 | 22% |
| Biopharma | 4 | 13% |

32 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 11 | 34% |
| Angel | 8 | 25% |
| Series B | 5 | 16% |
| Seed | 3 | 9% |
| Series C | 1 | 3% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 23 | 72% |
| Switzerland | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Novamab | Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $43.9M | Series B | Apr 24, 2026 |  |
| Hexaell Biotech | Hexaell Biotechnology Co., Ltd is a start-up company pioneering in stem cell and artificial organ. The disruptive technologies were original published in "Nature. 475(7356):386-9" and "Cell Stem Cell. 14(3):370-84" from Chinese Academy of Sciences. Hexaell Biotechnology had licensed iHep and HiHep technologies from ChineseAcademy of Sciences and developed medical devices of bio-artificial liver to replace liver function of human and cure liver failure diseases. Hexaell has finished pilot clinical studies in 6 liver failure patients in leading hepatopathy centers in China. | $14.6M | Series B | Apr 24, 2026 |  |
| Leman Biotech | Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $28.8M | Series A | Jan 26, 2026 |  |
| Cascade | Cascade produces novel medications that target nuclear receptors for treating metabolic disorders and inflammation. | $42.4M | Series B | Nov 28, 2025 |  |
| Sheng Sheng Biology | Sheng Sheng Biology is a biotechnology company that provides medical research and experimental development services. |  | Series A | Nov 21, 2024 |  |
| Leman Biotech | Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. |  | Series A | Nov 12, 2024 |  |
| Novamab | Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $24.4M | Series B | Jul 03, 2024 |  |
| Leman Biotech | Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $7M | Seed | Jun 18, 2024 |  |
| Leming Pharmaceuticals | Le Ming Pharmaceuticals is a pharmaceutical enterprise focusing on R&D, production and sales of innovative pharmaceutical preparation. | $13.8M | Venture - Series Unknown | Jun 07, 2024 |  |
| Hengsai Biological | Hengsai Bio is a tumor immunotherapy developer that engages in R&D and industrialisation of a new generation dendritic cell tumor vaccines. | $14M | Series A | Nov 27, 2023 |  |

10 of 32 investments shown.

## Co-investors
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 3 deals together
- [XtalPi](https://shizune.co/investors/profile/xtalpi) — VC Fund, 3 deals together
- [CSC Group](https://shizune.co/investors/profile/csc-group) — VC Fund, 2 deals together
- [Heaven-Sent Capital Management](https://shizune.co/investors/profile/heaven-sent-capital-management) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Shangshi Fund](https://shizune.co/investors/profile/shangshi-fund) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [MaC Venture Capital](https://shizune.co/investors/profile/mac-venture-capital) — VC Fund
- [DAA Ventures](https://shizune.co/investors/profile/daa-capital-partners) — VC Fund
- [Alpana Ventures](https://shizune.co/investors/profile/alpana-ventures) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Switzerland](https://shizune.co/investors/medical-vc-funds-switzerland)
- [Film Investors in China](https://shizune.co/investors/film-investors-china)
- [Film Investors in Asia](https://shizune.co/investors/film-investors-asia)
- [Film VC Funds in China](https://shizune.co/investors/film-vc-funds-china)

## FAQ

### What does Fuho Capital invest in?

Fuho Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Angel stage. Most of the 32 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Fuho Capital's check size?

Fuho Capital typically joins rounds of $425k–$2.8M at Angel, $709k–$15M at Series A and $2.8M–$44M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fuho Capital participates in.

### When did Fuho Capital last invest?

The most recent investment recorded for Fuho Capital closed in Apr 2026. Shizune tracks 32 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co